EVVIVAX

Curated by Signal

Developer of nucleic-acid-based immunotherapies

Overview

Developer of nucleic-acid-based immunotherapies. The company has developed Engineered Veterinary Vectored Immunotherapy and Vaccines based on DNA platform technologies. The product pipeline includes Tel-eVax and Erb-eVax a therapeutic cancer vaccine for canine tumors

Key facts

Founded: 2016
Headquarters: Rome, Italy
Stage: Sign up to view
Industry: Life Sciences Technology

Business model

2 products and services: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Biogin
Provider of dietary supplements for women's health
Life Sciences TechnologyRome, Italy
Testpaternita
Provider of genetic testing kits for individuals
Life Sciences TechnologyRome, Italy
GlucoMen Day
Manufacturer of continuous glucose monitoring system
Life Sciences TechnologyFlorence, Italy

About EVVIVAX

What does EVVIVAX do?

Developer of nucleic-acid-based immunotherapies.

Where is EVVIVAX headquartered?

EVVIVAX is headquartered in Rome, Italy.

When was EVVIVAX founded?

EVVIVAX was founded in 2016.

Which sector is EVVIVAX in?

EVVIVAX operates in Life Sciences Technology.

Who are EVVIVAX's competitors?

Companies similar to EVVIVAX include Biogin, Testpaternita, and GlucoMen Day.